Aignostics is an international, interdisciplinary company that powers the next generation of precision medicine and advances the fields of AI and pathology. Founded in 2018 as a spin-off from Charité Berlin, one of Europe's largest and most esteemed university hospitals, Aignostics leverages proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop cutting-edge insights for precision medicine.

Headquartered in Berlin with offices in New York, the company supports drug discovery, translational research, clinical trials, and companion diagnostic development across multiple therapeutic areas. Aignostics boasts a diverse team of over 120 employees with deep expertise in data science, machine learning, pathology, and biology, collaborating to transform drug development and improve patient outcomes.

Our mission is to transform drug development and improve patient outcomes through AI that delivers novel insights for precision medicine. Our team includes data scientists, machine learning engineers, pathologists, and biologists who provide expert input and oversight into all products and services.

We offer a range of rigorously developed products and services for precision medicine, including pathology foundation models and the Atlas H&E-TME tumor microenvironment profiling application. Our services include target and biomarker discovery, translational research, and digital diagnostics, supporting the evolving needs of precision medicine research.

The company maintains ISO 13485 and 27001 certifications and operates a GCP-ready clinical trial platform. Aignostics takes pride in its cutting-edge collaborations with academic partners in the EU and US, and proprietary access to multimodal data from over 30 million patients at leading university hospitals and laboratories.